JP2017528524A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528524A5
JP2017528524A5 JP2017534871A JP2017534871A JP2017528524A5 JP 2017528524 A5 JP2017528524 A5 JP 2017528524A5 JP 2017534871 A JP2017534871 A JP 2017534871A JP 2017534871 A JP2017534871 A JP 2017534871A JP 2017528524 A5 JP2017528524 A5 JP 2017528524A5
Authority
JP
Japan
Prior art keywords
alkyl
halogen
amino
nitro
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017534871A
Other languages
English (en)
Japanese (ja)
Other versions
JP6777638B2 (ja
JP2017528524A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/089865 external-priority patent/WO2016041511A1/en
Publication of JP2017528524A publication Critical patent/JP2017528524A/ja
Publication of JP2017528524A5 publication Critical patent/JP2017528524A5/ja
Application granted granted Critical
Publication of JP6777638B2 publication Critical patent/JP6777638B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017534871A 2014-09-19 2015-09-17 ベンゾ複素環化合物および薬剤 Expired - Fee Related JP6777638B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052617P 2014-09-19 2014-09-19
US62/052,617 2014-09-19
PCT/CN2015/089865 WO2016041511A1 (en) 2014-09-19 2015-09-17 Benzo-heterocyclic compounds and their applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020170524A Division JP2021008502A (ja) 2014-09-19 2020-10-08 ベンゾ複素環化合物および医薬組成物

Publications (3)

Publication Number Publication Date
JP2017528524A JP2017528524A (ja) 2017-09-28
JP2017528524A5 true JP2017528524A5 (enExample) 2018-10-18
JP6777638B2 JP6777638B2 (ja) 2020-10-28

Family

ID=55532567

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017534871A Expired - Fee Related JP6777638B2 (ja) 2014-09-19 2015-09-17 ベンゾ複素環化合物および薬剤
JP2020170524A Pending JP2021008502A (ja) 2014-09-19 2020-10-08 ベンゾ複素環化合物および医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020170524A Pending JP2021008502A (ja) 2014-09-19 2020-10-08 ベンゾ複素環化合物および医薬組成物

Country Status (8)

Country Link
US (2) US20170283408A1 (enExample)
EP (1) EP3194368B1 (enExample)
JP (2) JP6777638B2 (enExample)
KR (1) KR20170090408A (enExample)
CN (1) CN107087409B (enExample)
AU (1) AU2015317566B2 (enExample)
TW (1) TW201625527A (enExample)
WO (1) WO2016041511A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
PT3377488T (pt) 2015-11-19 2022-11-21 Incyte Corp Compostos heterocíclicos como imunomoduladores
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
PL3472167T3 (pl) 2016-06-20 2022-12-19 Incyte Corporation Związki heterocykliczne jako immunomodulatory
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102696516B1 (ko) * 2016-12-22 2024-08-22 인사이트 코포레이션 면역조절제로서의 벤조옥사졸 유도체
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
EP4212529B1 (en) 2018-03-30 2025-01-29 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
FI4219492T3 (fi) 2018-05-11 2025-02-17 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
CN108774219B (zh) * 2018-05-17 2021-05-04 中国药科大学 抑制pd-1/pd-l1的小分子化合物及其用途
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
KR102211062B1 (ko) 2019-02-27 2021-02-02 충남대학교산학협력단 신규한 나프탈이미드-벤조사이아졸 화합물 및 이를 포함하는 시아나이드 이온 및 트립토판 아미노산의 선택적 검출이 가능한 화학센서
CN109970729B (zh) * 2019-03-12 2024-01-26 西北农林科技大学 一种氟离子探针聚集态荧光增强型染料的合成方法
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN110407865B (zh) * 2019-08-02 2022-04-15 山东师范大学 基于苯磺酰胺结构的式(i)化合物及其制备方法与应用
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN115835909A (zh) 2020-05-05 2023-03-21 泰昂治疗公司 大麻素受体2型(cb2)调节剂和其用途
CN112250682B (zh) * 2020-11-02 2021-12-07 河南大学 一种芳杂环修饰的萘酰亚胺衍生物及其制备方法和用途
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
PE20231438A1 (es) 2020-11-06 2023-09-14 Incyte Corp Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
TW202325306A (zh) 2021-09-02 2023-07-01 美商天恩治療有限公司 改良免疫細胞之生長及功能的方法
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
EP4554943A1 (en) 2022-07-14 2025-05-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN115385890B (zh) * 2022-07-19 2023-08-08 杭州庆正鸿科技有限公司 一种1,8萘酰亚胺衍生物及其制备方法与应用
CN117143076A (zh) * 2023-09-01 2023-12-01 河南大学 喹喔啉修饰的萘酰亚胺-多胺缀合物及其制备方法和应用
CN117285546A (zh) * 2023-09-08 2023-12-26 河南大学 咪唑并噻唑修饰的萘酰亚胺-多胺缀合物、制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2423548C2 (de) * 1974-05-15 1984-08-23 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung von 4-Amino1,8-naphthalimid-Verbindungen
DE3942280A1 (de) * 1989-12-21 1991-06-27 Knoll Ag N-substituierte naphthalimide, ihre herstellung und verwendung
AU760136B2 (en) * 1998-11-25 2003-05-08 Merck Patent Gmbh Substituted benzo(DE)isoquinoline-1,3-diones
CN1857221A (zh) * 2006-04-14 2006-11-08 济南帅华医药科技有限公司 一种同载铂类化合物及其增效剂的抗癌缓释剂
EP2118065B1 (en) 2007-01-11 2013-08-14 Council of Scientific & Industrial Research Substituted 1H-benz[de]isoquinoline-1,3-diones
HUP0700433A2 (en) * 2007-06-21 2009-03-30 Avidin Kutato Compounds influencing development or functioning of cellular vesicular systems particularly lipid droplets, pharmaceutical compositions containing these compounds and use them for treatment of illnesses
WO2009089537A2 (en) * 2008-01-11 2009-07-16 Northwestern University Anti-cancer compounds
CN102206203B (zh) * 2011-04-04 2013-06-19 大连理工大学 含有苯并咪唑的萘酰亚胺衍生物的合成及其在抗肿瘤上的应用
CN102731493B (zh) * 2012-07-08 2014-06-25 大连理工大学 一类抗肿瘤含苯并噻唑杂环结构的化合物及其应用

Similar Documents

Publication Publication Date Title
JP2017528524A5 (enExample)
EA201890888A1 (ru) Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53
JP2017530984A5 (enExample)
AR102094A1 (es) Inhibidores de proteínas kras con una mutación g12c
JP2017515802A5 (enExample)
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
MY206521A (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
SI3009431T1 (en) 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
JP2014518882A5 (enExample)
JP2015510886A5 (enExample)
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
EA201290237A1 (ru) Киназные ингибиторы
MX2013012588A (es) Inhibidores de cinasa.
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
WO2014105958A3 (en) Fused pyrimidine compounds and use thereof
RU2016110096A (ru) Новое хинолин-замещенное соединение
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
NZ726360A (en) Phosphatidylinositol 3-kinase inhibitors
ZA202002762B (en) Benzimidazole derivatives and their uses
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
PE20142244A1 (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina